Overexpression of claudin-4 may be involved in endometrial tumorigenesis

Pan,Xiao-Yu; Li,Xue; Che,Yan-Ci; Li,Hong-Yan; Li,Xin; Zhang,Yun; Yang,Xin

doi:10.3892/ol.2013.1198

Overexpression of claudin-4 may be involved in endometrial tumorigenesis

Authors:
- Xiao-Yu Pan
- Xue Li
- Yan-Ci Che
- Hong-Yan Li
- Xin Li
- Yun Zhang
- Xin Yang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Pathology, Beijing Chao Yang Hospital of Capital Medical University, Beijing 100020, P.R. China, Department of Obstetrics and Gynecology, The Affiliated Hospital of QingDao University Medical School, QingDao 266003, P.R. China, Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: February 18, 2013 https://doi.org/10.3892/ol.2013.1198
Pages: 1422-1426

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To clarify the role of claudin-4 in endometrial tumorigenesis and to explore whether claudin-4 could be a potentially useful agent in the treatment of endometrial carcinoma, the expression of claudin-4 in endometrial carcinoma was investigated. The relationship between therapy with anti-neoplastic agents and the expression of claudin-4 was also analyzed using an endometrial carcinoma xenograft model. The expression of claudin-4 in endometrial endometrioid adenocarcinoma (EEC) and normal human endometrial tissue was determined using immunohistochemistry and real-time PCR. Ninety female BALB/c nu/nu mice were transplanted with Ishikawa endometrial cancer cells. The mice were divided into three groups with different intraperitoneal treatments: cisplatin, paclitaxel or saline solution. After the observation period tumors were extracted and stained with monoclonal antibody against claudin-4. The mRNA expression of claudin-4 was also detected using real-time PCR. Expression of claudin-4 was significantly increased at both protein and mRNA levels in the EEC group compared with the group of normal cyclic endometrium. In the study of Ishikawa xenografts, no significant changes in tumor volume and claudin-4 expression were shown in the paclitaxel group compared with the control group. A significant reduction of tumor growth and a significant decrease in claudin-4 expression were observed in the cisplatin group. These results demonstrate that claudin-4 is strongly expressed in EEC. Claudin-4 is a useful biomarker in the treatment of patients with endometrial carcinoma.

View Figures

View References

1	Di Cristofano A and Ellenson LH: Endometrial carcinoma. Annu Rev Pathol. 2:57–85. 2007.
2	Macwhinnie N and Monaghan H: The use of P53, PTEN, and CerbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer. 14:938–946. 2004. View Article : Google Scholar : PubMed/NCBI
3	Wu W, Slomovitz BM, Celestino J, Chung L, Thornton A and Lu KH: Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas. Cancer Res. 63:6195–6199. 2003.PubMed/NCBI
4	Matter K and Balda MS: Functional analysis of tight junctions. Methods. 30:228–234. 2003. View Article : Google Scholar : PubMed/NCBI
5	Swisshelm K, Macek R and Kubbies M: Role of claudins in tumorigenesis. Adv Drug Deliv Rev. 57:919–928. 2005. View Article : Google Scholar : PubMed/NCBI
6	Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 65:9603–9606. 2005. View Article : Google Scholar : PubMed/NCBI
7	Yoshida H, Sumi T, Zhi X, Yasui T, Honda K and Ishiko O: Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res. 31:1271–1277. 2011.PubMed/NCBI
8	Hayes MP and Ellenson LH: Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 116:286–289. 2010. View Article : Google Scholar : PubMed/NCBI
9	Long H, Crean CD, Lee WH, Cummings OW and Gabig TG: Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 61:7878–7881. 2001.
10	Zhu Y, Brännström M, Janson PO and Sundfeldt K: Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer. 118:1884–1891. 2006. View Article : Google Scholar
11	Nichols LS, Ashfaq R and Iacobuzio-Donahue CA: Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol. 121:226–230. 2004. View Article : Google Scholar : PubMed/NCBI
12	Shang X, Lin X, Alvarez E, Manorek G and Howell SB: Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia. 14:974–985. 2012.PubMed/NCBI
13	Santin AD, Bellone S, Marizzoni M, et al: Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer. 109:1312–1322. 2007. View Article : Google Scholar : PubMed/NCBI
14	Villena-Heinsen C, Friedrich M, Ertan AK, Farnhammer C and Schmidt W: Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride. Anticancer Drugs. 9:557–563. 1998. View Article : Google Scholar : PubMed/NCBI
15	Armstrong DK, Bundy B, Wenzel L, et al: Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Chen L, He X, et al: Enhancement of therapeutic effectiveness by combining liposomal honokiol with cisplatin in ovarian carcinoma. Int J Gynecol Cancer. 18:652–659. 2008. View Article : Google Scholar : PubMed/NCBI
17	Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Natali PG and Bagnato A: Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Can J Physiol Pharmacol. 88:676–681. 2010.PubMed/NCBI
18	Kominsky SL, Vali M, Korz D, et al: Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol. 164:1627–1633. 2004. View Article : Google Scholar
19	Litkouhi B, Kwong J, Lo CM, et al: Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia. 9:304–314. 2007. View Article : Google Scholar
20	Gao Z, Xu X, McClane B, et al: C terminus of Clostridium perfringens enterotoxin downregulates CLDN4 and sensitizes ovarian cancer cells to Taxol and Carboplatin. Clin Cancer Res. 17:1065–1074. 2011.